Search Results
Your search for The ASCO Post matches 17393 pages
Showing 12101 - 12150
Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control
Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local control of this disease. (Abstract 324)
Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
Maria Werner-Wasik, MD, on Issues in Lung Toxicity
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation to thoracic vertebral bodies, radiation pneumonitis, and upfront SBRT. (Scientific Session 39)
ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...
ASTRO 2016: Advances in Radiation Therapy Have Improved Survival Rates for Patients With Early-Stage Lung Cancer
A new analysis of records in the Veterans Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non–small cell lung cancer (NSCLC) in recent years, according to research presented...
ASTRO 2016: Radiation Boost Reduces Local Tumor Recurrence for Patients With DCIS Following WBRT
A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with ductal carcinoma in situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research ...
ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
ASTRO 2016: Unmet Need for Radiation Therapy Found Among Nearly Half of Eligible Cancer Patients in Nine Developing Countries
Although approximately 50% of cancer patients in developing countries need radiation therapy to treat their disease, up to half of these patients do not have access to it, according to research presented by Rosenblatt et al at the 58th Annual Meeting of the American Society for Radiation Oncology...
ASTRO 2016: Hypofractionated Radiation Therapy Can Reduce Treatment Time With Comparable Quality of Life for Patients With Prostate Cancer
For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy offers comparable health-related quality of life outcomes in one-third less treatment time than conventional radiation therapy, according to research presented by Watkins Bruner et al at the 58th...
ASTRO 2016: Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients With Early-Stage Lung Cancer
Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) rose from roughly 40% to 60% over the past decade, concurrent with the increasing adoption of SBRT, according to research presented by Dalwadi et al...
ASTRO 2016: Cervical and Endometrial Cancer Patients Report Fewer Side Effects and Better Quality of Life With IMRT
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy, according to research presented by Klopp et al at...
Thomas J. Lynch, Jr, MD, on Personalized Care and Radiation Oncology in Lung Cancer
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Richard T. Hoppe, MD, on Lymphoma: Improving Outcomes
Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)
Bradley R. Prestidge, MD, on Prostate Cancer: Initial Findings of NRG Oncology/RTOG 0232
Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer....
Alan Pollack, MD, PhD, on Prostate Cancer: Postprostatectomy Radiotherapy
Alan Pollack, MD, PhD, of the University of Miami Health System, summarizes a session that included discussion of outcomes, dose response, oligometastatic disease, and gene predictor of response. (Presentations 228-235)
Joanne B. Weidhaas, MD, PhD, on Head and Neck Cancer: Results of the NRG Oncology/RTOG 0522 Study
Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immunity in head and neck cancer. (Abstract LBA-11)
Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Takeshi Kodaira, MD, PhD, on Glottic Cancer: Results of a Japan Clinical Oncology Group Study
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Louis Harrison, MD, on Radiation Oncology and the Future of Health Care
Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.
Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery 126
Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world. (Scientific Session 10)
Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future 126
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)
Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity 126
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Brian Kavanagh, MD, MPH: Looking Ahead With ASTRO’s President-Elect
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective
Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.
Douglas W. Arthur, MD, on Breast-Preserving Surgery: Results From NRG Oncology/RTOG 1014 126
Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)
Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...
Blood Biomarkers in Abiraterone- or Enzalutamide-Resistant Prostate Cancer Tumor Cells
While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...
Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk
In a new study, men who underwent vasectomy did not have an increased risk of prostate cancer, nor were they more likely to die from prostate cancer than men who did not receive this procedure. According to the researchers, this is the largest prospective study of vasectomy and fatal prostate...
Saul J. Sharkis, PhD, Stem Cell Researcher, Dies
Saul J. Sharkis, PhD, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died on September 4. He was 72. Dr. Sharkis was Professor of Oncology at the Johns Hopkins University School of Medicine and a faculty...
Study Confirms Benefit of Cobimetinib Plus Vemurafenib in Advanced BRAF V600–Mutant Melanoma
As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of...
Combining Ipilimumab With Radiotherapy in Advanced Melanoma
The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. Sebastian Theurich, MD, of the Center for Integrated Oncology at the University Hospital of Cologne in Germany, and colleagues...
Olanzapine Combination Reduces Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
Updated Outcomes, Impact of Age in Multiple Myeloma
Updated Outcomes, Impact of Age in Multiple Myeloma As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone...
2016-2017 Oncology Meetings
OCTOBER International Cancer Imaging Society Meeting and 16th Annual Teaching CourseOctober 3-5 • Glasgow, ScotlandFor more information:http://www.icimagingsociety.org.uk/index.cfm?task=meetings 9th International Workshop on Waldenstrom’s Macroglobulinemia & Symposia on Multiple MyelomaOctober...
The Anesthesia Era 1845–1875 Carte de Visite, London, circa 1858
For over 2,500 years, bloodletting was the backbone of medical therapy. To date, it is the longest-running therapeutic tradition known. First practiced in ancient Egypt, its use spread throughout Western civilization. The therapy was still performed in Southern rural America until the 1910s. One...
Emily L. Sedgwick, MD, Receives Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism
Emily L. Sedgwick, MD, Associate Professor of Breast Imaging in the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center, has been named the 2016 recipient of the Ben and Margaret Love Foundation Bobby Alford Award for...
Michael Maitland, MD, PhD, Named Director of Therapeutics for the Inova Center for Personalized Health
Inova Health System is pleased to welcome Michael Maitland, MD, PhD, where he will serve as the new Director of Therapeutics for the Inova Center for Personalized Health and as Associate Director of Cancer Therapeutics for the Inova Schar Cancer Institute. Dr. Maitland comes to Inova from the...
An Ovarian Cancer Expert’s Guide Offers Insight, Wisdom, and Hope
There have been numerous books explicating the information a physician or patient needs to know about our current clinical state in the diagnosis and treatment of ovarian cancer. Many of them are good, but rare is a well-written book in the cancer genre that offers solid scientific hope exceeding ...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...
2016 Lasker Awards Honor Scientists for Basic and Clinical Medical Research, Special Achievement
The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. Kaelin, MD; Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS; and Gregg L. Semenza, MD, PhD for basic medical research; Ralf F.W. Bartenschlager, PhD; Charles M. Rice, PhD;...
The Halifax Project: A New Approach to Combination Therapy
On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...
Clinical Trials Actively Recruiting Patients With Acute Lymphoblastic Leukemia
Phase I Study Title: Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: Northwestern University, National...
Pioneer in Chemoradiation Robert B. Livingston, MD, Dies
Over the past couple of decades, chemoradiation for several cancers, such as lung and breast, has advanced in efficacy and side-effect tolerance, prolonging survival and quality of life for patients. One of the pioneers in chemoradiation, Robert B. Livingston, MD, died on September 8, 2016. Dr....
Recognizing the Unique Experiences of Cancer Among Adolescent and Young Adult Survivors
Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...
FDA Approves Blinatumomab for Use in Pediatric Patients With Ph-Negative Relapsed or Refractory B-Cell Precursor ALL
The U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor acute...
Bassel El-Rayes, MD, to Hold John Kauffman Family Professorship at Winship
Bassel F. El-Rayes, MD, Associate Director of Clinical Research at Winship Cancer Institute of Emory University, was selected to hold the John Kauffman Family Professorship for Pancreatic Cancer Research. The new position was created to support an outstanding leader in the field of pancreatic...
Ainel Sewell, MD, to Lead Houston Methodist Breast Care Center
Ainel Sewell, MD, has been named the Medical Director of the Breast Care Center at Houston Methodist Willowbrook Hospital. Dr. Sewell is a board-certified radiologist specializing in breast imaging. “Being asked to lead the breast care center at Houston Methodist Willowbrook Hospital is an...
Jeff Allen, PhD, Named Friends’ First CEO
Friends of Cancer Research (Friends) has announced that its Executive Director, Jeff Allen, PhD, will assume the role of President and CEO of the organization. Friends’ founder, Ellen Sigal, PhD, will continue with the organization as Board Chair. Dr. Allen will become the day-to-day lead of...
Patricia LoRusso, DO, Named Chair of AACR’s Women in Cancer Research
Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Director of Innovative Medicine at Yale Cancer Center, has been named Chair of the Women in Cancer Research (WICR) Council of the American Association for Cancer Research (AACR). WICR is a membership group within the AACR ...
Allison Aggon, DO, Joins Fox Chase Cancer Center
Allison Aggon, DO, has joined the Department of Surgical Oncology at Fox Chase Cancer Center, focusing on breast surgery. Dr. Aggon comes to Fox Chase from Crozer-Keystone Health System-Delaware County, where she has practiced as a breast surgeon and served as Medical Director of the Center for...
